prikaz prve stranice dokumenta Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
  Download
PDF 1012.49 KB
master's thesis
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
Zagreb: University of Zagreb, School of Medicine, 2024. urn:nbn:hr:105:870483
Singh, Yasho-Victoria Gayatri Calla
University of Zagreb
School of Medicine
Department of Neurology

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Singh, Y. V. G. C. (2024). Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:870483

Singh, Yasho Victoria Gayatri Calla. "Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)." Master's thesis, University of Zagreb, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:105:870483

Singh, Yasho Victoria Gayatri Calla. "Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)." Master's thesis, University of Zagreb, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:105:870483

Singh, Y. V. G. C. (2024). 'Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)', Master's thesis, University of Zagreb, School of Medicine, accessed 27 December 2024, https://urn.nsk.hr/urn:nbn:hr:105:870483

Singh YVGC. Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2024 [cited 2024 December 27] Available at: https://urn.nsk.hr/urn:nbn:hr:105:870483

Y. V. G. C. Singh, "Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2024. Available at: https://urn.nsk.hr/urn:nbn:hr:105:870483

Metadata
TitleMyelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
Title (croatian)Bolest povezana s mijelinskim oligodendrocitnim glikoproteinom (MOGAD)
AuthorYasho-Victoria Gayatri Calla Singh
MentorTereza Gabelić (mentor)
Committee memberTereza Gabelić (predsjednik povjerenstva)
Committee memberMario Habek (član povjerenstva)
Committee memberŽeljka Petelin Gadže (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Neurology)
Zagreb
Defense date and country2024-07-12, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract
Myelin Oligodendrocyte Glycoprotein (MOG) is a component of myelin found in the mammalian Central Nervous System (CNS) and is present on both myelin sheaths and oligodendrocyte plasma membranes. In 2007, MOG became popular since anti-MOG antibodies were found in patients with neuroinflammatory conditions like optic neuritis, myelitis, and neuromyelitis optica spectrum disorder (NMOSD) lacking aquaporin 4 (AQP4) antibodies, along with brainstem and cerebral cortical encephalitis. This discovery has led to the classification of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), a clinical condition distinct from multiple sclerosis (MS) and traditional NMOSD. Diagnosing MOGAD poses a unique challenge due to varying interpretations of clinical symptoms, imaging, and serological findings among researchers and its similarity with MS and AQP4 IgG+ NMOSD. Treatment strategies for MOGAD attacks include intravenous steroids or plasma exchange, while long-term management approaches are still being studied. Current treatments draw heavily from NMOSD protocols, such as immunosuppressants like azathioprine and mycophenolate mofetil. However, the fact that there is moderate effectiveness of drugs like Rituximab in MOGAD, a key player in NMOSD treatment, proves that more than one size fits treatment plan will be needed on MOGAD. Research on therapies targeting interleukin 6 (IL 6), a cytokine involved in the immune response, and other innovative methods such as T cell modulation, is ongoing to keep up with the changing landscape of MOGAD treatment. The ongoing research on MOGAD is a beacon of hope, underscoring the need for implementation of global diagnostic criteria and deeper insights into its causes. This research is instrumental in supporting tailored treatments and understanding the disease's prevalence and genetic influences. The collaborative efforts across countries, focused on personalized treatment plans, are essential for improving outcomes and minimizing complications in individuals with MOGAD.
Abstract (croatian)
Mijelinski oligodendrocitni glikoprotein (MOG) sastavni je dio mijelina koji se nalazi u središnjem živčanom sustavu (CNS) sisavaca i prisutan je i na mijelinskim ovojnicama i na plazma membranama oligodendrocita. Godine 2007. MOG je postao popularan jer su anti-MOG antitijela pronađena kod pacijenata s neuroupalnim stanjima kao što su optički neuritis, mijelitis i poremećaj optičkog spektra neuromijelitisa (NMOSD) kojima nedostaju antitijela na akvaporin 4 (AQP4), zajedno s zahvaćanjem moždanog debla i cerebralnim kortikalnim encefalitisom. Ovo otkriće dovelo je do klasifikacije bolesti povezane s mijelinskim oligodendrocitnim glikoprotein antitijelima (MOGAD), kliničkog stanja koje se razlikuje od multiple skleroze (MS) i tradicionalnog NMOSD-a. Dijagnosticiranje MOGAD-a predstavlja jedinstveni izazov zbog različitih tumačenja kliničkih simptoma, neuroradioloških slika i seroloških nalaza među istraživačima te njegove sličnosti s MS-om i AQP4 IgG+ NMOSD-om. Strategije liječenja za MOGAD relapse uključuju intravenske steroide ili izmjenu plazme, dok se dugoročni pristupi liječenju još proučavaju. Trenutačni tretmani uvelike se oslanjaju na NMOSD protokole, te uključuju imunosupresive kao što su azatioprin i mikofenolat mofetil. Međutim, činjenica da postoji umjerena učinkovitost lijekova poput rituximaba u MOGAD-u, ključnom lijeku u liječenju NMOSD-a, dokazuje da će za MOGAD biti potreban drugačiji plana liječenja. Istraživanje terapija usmjerenih na interleukin 6 (IL 6), citokin uključen u imunološki odgovor, i druge inovativne metode kao što su imodulacija T stanica, nastavljaju se kako bi se išlo u korak s promjenjivim krajolikom MOGAD liječenja. Istraživanje MOGAD-a koje je u tijeku je svjetionik nade, naglašavajući potrebu za implementacijom globalnih dijagnostičkih kriterija i dubljim uvidom u njegovu etiologiju. Ovo istraživanje je ključno u podržavanju prilagođenih tretmana i razumijevanju prevalencije bolesti i genetskih utjecaja. Zajednički napori među zemljama, usmjereni na personalizirane planove liječenja, ključni su za poboljšanje ishoda i minimiziranje komplikacija kod pojedinaca s MOGAD-om.
Keywords
Keywords (croatian)
Languageenglish
URN:NBNurn:nbn:hr:105:870483
Study programmeTitle: Medicine (in English language)
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-10-21 09:02:43